Rare bleeding disorders and advances in gene therapy

Blood Coagul Fibrinolysis. 2019 Dec;30(8):371-378. doi: 10.1097/MBC.0000000000000852.

Abstract

: Rare bleeding disorders usually begin in childhood and manifest as varying degrees of bleeding, which can be life-threatening in severe cases. With the development of gene editing technology, it is expected that hereditary coagulation factor disorders will someday be fundamentally cured by gene therapy. On account of their rarity, comprehension of these diseases is essential for the application of new treatment strategies. We have compiled the features of some newly discovered mutations of prothrombin, factor VII, and factor X in recent years. In addition, this review introduces the advances and obstacles in gene therapy.

Publication types

  • Review

MeSH terms

  • Blood Coagulation Disorders / therapy*
  • Factor VII / genetics
  • Factor X / genetics
  • Genetic Therapy / methods*
  • Hemorrhagic Disorders / therapy*
  • Humans
  • Mutation
  • Prothrombin / genetics
  • Rare Diseases / therapy*

Substances

  • Factor VII
  • Prothrombin
  • Factor X